Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2016 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
NTLA on Nasdaq
Shares outstanding
107,809,066
Price per share
$8.99
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
104,170,311
Total reported value
$1,798,838,423
% of total 13F portfolios
0%
Share change
+5,039,963
Value change
+$103,534,405
Number of holders
277
Price from insider filings
$8.99
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ARK Investment Management LLC 11% $205,844,204 11,919,178 ARK Investment Management LLC 30 Sep 2025
VANGUARD GROUP INC 10% $84,678,509 10,189,953 The Vanguard Group 31 Dec 2024
BlackRock, Inc. 8.2% $70,244,546 8,453,014 BlackRock, Inc. 31 Mar 2025
Contrarius Investment Management Ltd 5.5% $101,719,195 5,889,936 Contrarius Investment Management Ltd 30 Sep 2025
GOLDMAN SACHS GROUP INC 5.1% $94,954,991 5,498,262 THE GOLDMAN SACHS GROUP, INC. 30 Sep 2025
STATE STREET CORP 4.4% $37,480,269 4,510,261 STATE STREET CORPORATION 31 Mar 2025

As of 30 Sep 2025, 277 institutional investors reported holding 104,170,311 shares of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA). This represents 97% of the company’s total 107,809,066 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) together control 80% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
ARK Investment Management LLC 11% 11,919,178 -8.4% 1.2% $205,844,200
VANGUARD GROUP INC 10% 11,044,820 +1.8% 0% $190,744,040
BlackRock, Inc. 8.6% 9,275,817 -7.5% 0% $160,193,355
MORGAN STANLEY 5.6% 6,022,576 +46% 0.01% $104,009,912
Contrarius Group Holdings Ltd 5.5% 5,889,936 +279% 4.6% $101,719,195
STATE STREET CORP 4.6% 4,970,869 +23% 0% $85,846,908
GOLDMAN SACHS GROUP INC 4% 4,278,677 +109% 0.01% $73,892,752
REGENERON PHARMACEUTICALS, INC. 3.4% 3,702,995 0% 9.1% $63,950,724
BAKER BROS. ADVISORS LP 2.5% 2,746,674 +2.7% 0.34% $47,435,060
GEODE CAPITAL MANAGEMENT, LLC 2.4% 2,588,854 -0.67% 0% $44,714,752
TWO SIGMA INVESTMENTS, LP 2.3% 2,449,607 +7.6% 0.06% $42,304,713
Sumitomo Mitsui Trust Group, Inc. 2.2% 2,354,856 -12% 0.02% $40,668,363
Amova Asset Management Americas, Inc. 2.2% 2,354,856 -12% 0.39% $40,621,266
D. E. Shaw & Co., Inc. 2.1% 2,228,400 +170% 0.03% $38,484,468
TWO SIGMA ADVISERS, LP 2% 2,163,417 +3.4% 0.07% $37,362,212
FMR LLC 1.7% 1,852,292 +22% 0% $31,989,079
DIMENSIONAL FUND ADVISORS LP 1.6% 1,757,294 -5.8% 0.01% $30,346,421
VOLORIDGE INVESTMENT MANAGEMENT, LLC 1.5% 1,610,205 +3.7% 0.09% $27,808,240
JUPITER ASSET MANAGEMENT LTD 1.3% 1,361,849 0.2% $23,519,132
UBS Group AG 1% 1,108,186 +26% 0% $19,138,372
NORTHERN TRUST CORP 0.84% 906,292 -0.3% 0% $15,651,663
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.83% 890,361 +17% 0.02% $15,376,534
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.81% 873,188 +1.9% 0% $15,079,957
STIFEL FINANCIAL CORP 0.72% 778,516 -0.83% 0.01% $13,444,998
ARMISTICE CAPITAL, LLC 0.62% 672,000 +3.4% 0.36% $11,605,440

Institutional Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 440,112 $3,968,503 +$189,172 $8.99 17
2025 Q3 104,170,311 $1,798,838,423 +$103,534,405 $17.27 277
2025 Q2 99,520,897 $933,579,792 -$6,825,658 $9.38 277
2025 Q1 101,252,381 $719,981,345 +$1,659,582 $7.11 289
2024 Q4 99,191,549 $1,156,525,724 -$49,302,844 $11.66 288
2024 Q3 93,188,112 $1,914,885,599 +$52,687,081 $20.55 277
2024 Q2 90,118,237 $2,016,932,908 -$33,057,144 $22.38 286
2024 Q1 90,994,794 $2,502,941,003 +$158,724,377 $27.51 279
2023 Q4 85,253,157 $2,599,308,572 +$153,798,142 $30.49 289
2023 Q3 80,150,230 $2,534,451,262 +$57,616,066 $31.62 281
2023 Q2 78,283,933 $3,190,579,654 -$9,432,957 $40.78 288
2023 Q1 78,716,838 $2,928,484,579 +$27,166,066 $37.27 288
2022 Q4 78,108,132 $2,724,660,295 +$325,216,887 $34.89 294
2022 Q3 68,149,786 $3,811,906,455 -$6,962,154 $55.96 308
2022 Q2 67,593,487 $3,442,253,307 +$98,077,804 $51.76 282
2022 Q1 65,174,223 $4,718,129,955 -$27,349,229 $72.67 341
2021 Q4 64,197,108 $7,594,973,150 +$200,734,926 $118.24 361
2021 Q3 62,179,774 $8,341,966,333 +$38,202,306 $134.15 354
2021 Q2 61,943,081 $10,039,072,441 +$39,075,135 $161.91 329
2021 Q1 62,997,292 $5,055,620,165 +$268,264,167 $80.25 255
2020 Q4 61,851,171 $3,364,841,363 +$187,799,640 $54.40 239
2020 Q3 56,492,124 $1,125,276,243 +$49,648,218 $19.88 161
2020 Q2 53,928,267 $1,127,243,500 +$160,801,520 $21.02 160
2020 Q1 46,446,764 $568,083,328 +$9,021,271 $12.23 133
2019 Q4 45,615,533 $669,178,528 +$24,351,485 $14.67 137
2019 Q3 44,102,636 $588,745,766 +$69,153,421 $13.35 131
2019 Q2 38,816,811 $635,365,544 +$86,588,206 $16.37 142
2019 Q1 33,462,480 $569,908,589 +$44,514,644 $17.08 142
2018 Q4 31,523,455 $430,244,776 +$12,114,608 $13.65 136
2018 Q3 29,098,874 $832,839,044 +$7,443,896 $28.62 149
2018 Q2 28,851,341 $789,266,553 +$71,304,782 $27.36 151
2018 Q1 26,414,691 $557,070,367 +$49,316,700 $21.09 127
2017 Q4 24,300,186 $467,047,800 +$127,200,241 $19.22 110
2017 Q3 17,671,668 $439,163,056 +$20,668,372 $24.85 84
2017 Q2 16,801,771 $268,836,976 +$2,831,017 $16.00 81
2017 Q1 16,738,696 $235,847,748 -$10,683,400 $14.09 73
2016 Q4 18,384,582 $241,018,660 -$6,133,604 $13.11 67
2016 Q3 14,253,796 $242,822,100 +$573,360 $17.02 64
2016 Q2 14,055,535 $300,085,720 +$298,405,720 $21.35 61
2016 Q1 215 $4,000 $18.60 1